Home › Marginal Zone Lymphoma › Washington
Marginal Zone Lymphoma clinical trials in Washington
9 studies for Marginal Zone Lymphoma are looking for participants at sites in Washington.
Cities in Washington
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Swedish Cancer Institute (SCI), Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study of ARC-02 in B-cell NHL
- Summit Cancer Centers - North Spokane, Spokane
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.